Mark A Reddish

Title: Mark A Reddish: Innovator in Cellular Vaccines

Introduction

Mark A Reddish is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of immunology, particularly in the development of cellular vaccines for cancer and viral diseases. His innovative approach combines advanced techniques in T-cell activation with practical applications in medical treatments.

Latest Patents

Mark A Reddish holds a patent for "Lipid-modified muc-1 derivatives." This invention describes a method for generating a mixture of activated T-cells by combining a plurality of peripheral blood lymphocytes (PBLs) with an antigen-loaded liposome. The process produces antigen-loaded PBLs, which are then combined with naive, anergic, or memory T-cells to create activated T-cells. This activation can occur both in vivo and in vitro. The resulting antigen-loaded PBLs and activated T-cells have potential uses as cellular vaccines for the treatment of cancer and viral diseases. He has 1 patent to his name.

Career Highlights

Throughout his career, Mark has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Biomira, Inc. and Oncothyreon Inc. These experiences have allowed him to apply his innovative ideas in real-world settings, contributing to advancements in cancer treatment.

Collaborations

Mark A Reddish has collaborated with several professionals in his field, including Babita Agrawal and Mark J Krantz. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Mark A Reddish is a distinguished inventor whose work in cellular vaccines has the potential to transform cancer and viral disease treatments. His innovative methods and collaborations highlight his commitment to advancing medical science.